Abstract
Apart from the absence of targeted therapies, poor prognosis in TNBC has
affected the clinical outcome of the disease and has led to cause high mortality rate
amongst diseased individuals. The discovery of potential biomarkers to determine the
prognostic and predictive value may play a vital role in the development of an effective
therapeutic approach and may improve the OS, DFS, and DMFS. This chapter
highlighted the role of histological subtyping, lymph node status, lymphovascular
invasion, miRNA, Ki-67, TILs, and BRCAness as prognostic markers of diseases.
Nevertheless, patient selection and choice of treatment strategy will greatly impact the
clinical efficacy of these prognostic markers but will remain to be a matter of further
exploration.